HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) CME: Take the course for this article: Volume 61, Number 6, September 23, 2003 Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burke, G. Articles by Beeson, D. Search for Related Content PubMed PubMed Citation Articles by Burke, G. Articles by Beeson, D. Related Collections Myasthenia All Pediatric All Genetics

Rapsyn mutations in hereditary myasthenia

Distinct early- and late-onset phenotypes

From the Department of Clinical Neurology (Drs. Burke, Hilton–Jones, and Palace) and Neurosciences Group (Drs. Cossins, Vincent, Newsom–Davis, and Beeson, S. Maxwell and G. Owens), Weatherall Institute of Molecular Medicine, Department of Clinical Neurology, University of Oxford, and Department of Paediatric Neurology (Dr. Robb), Guy’s and St. Thomas’s Hospital, London, UK; and Department of Clinical Neurological Sciences (Dr. Nicolle), University of Western Ontario, London, Ontario, Canada.

Address correspondence and reprint requests to Dr. D. Beeson, Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK; e-mail: dbeeson{at}hammer.imm.ox.ac.uk

Rapsyn mutations in 16 unrelated patients with a congenital/hereditary myasthenic syndrome were identified, and a mutation (N88K) common to each of them was found. Two distinct phenotypes were noted: early and late onset. The former is frequently associated with arthrogryposis multiplex congenita and life-threatening crises. The late-onset phenotype developed in adolescence or adulthood and was initially mistaken for seronegative myasthenia gravis. Recognition of this late-onset phenotype should prevent inappropriate immunotherapy.

This article has been cited by other articles:

				I. Bosma, L. Douw, F. Bartolomei, J. J. Heimans, B. W. van Dijk, T. J. Postma, C. J. Stam, J. C. Reijneveld, and M. Klein Synchronized brain activity and neurocognitive function in patients with low-grade glioma: A magnetoencephalography study Neuro-oncol, January 1, 2008; 10(5): 734 - 744. [Abstract] [Full Text] [PDF]

				J. S. Muller, A. Herczegfalvi, J. J. Vilchez, J. Colomer, L. L. Bachinski, V. Mihaylova, M. Santos, U. Schara, M. Deschauer, M. Shevell, et al. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes Brain, June 1, 2007; 130(6): 1497 - 1506. [Abstract] [Full Text] [PDF]

				J. Palace, D. Lashley, J. Newsom-Davis, J. Cossins, S. Maxwell, R. Kennett, S. Jayawant, Y. Yamanashi, and D. Beeson Clinical features of the DOK7 neuromuscular junction synaptopathy Brain, June 1, 2007; 130(6): 1507 - 1515. [Abstract] [Full Text] [PDF]

				G. O. Skeie, H. Aurlien, J. S. Muller, H. Lochmuller, G. Norgard, and L. A. Bindoff Unusual features in a boy with the rapsyn N88K mutation Neurology, December 26, 2006; 67(12): 2262 - 2263. [Full Text] [PDF]

				J. S. Muller, S. K. Baumeister, V. M. Rasic, S. Krause, S. Todorovic, K. Kugler, W. Muller-Felber, A. Abicht, and H. Lochmuller Impaired receptor clustering in congenital myasthenic syndrome with novel RAPSN mutations Neurology, October 10, 2006; 67(7): 1159 - 1164. [Abstract] [Full Text] [PDF]

				J. S. Muller, S. K. Baumeister, U. Schara, J. Cossins, S. Krause, M. v. d. Hagen, A. Huebner, R. Webster, D. Beeson, H. Lochmuller, et al. CHRND mutation causes a congenital myasthenic syndrome by impairing co-clustering of the acetylcholine receptor with rapsyn Brain, October 1, 2006; 129(10): 2784 - 2793. [Abstract] [Full Text] [PDF]

				J. Cossins, G. Burke, S. Maxwell, H. Spearman, S. Man, J. Kuks, A. Vincent, J. Palace, C. Fuhrer, and D. Beeson Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations Brain, October 1, 2006; 129(10): 2773 - 2783. [Abstract] [Full Text] [PDF]

				M. Losen, M. H. W. Stassen, P. Martinez-Martinez, B. M. Machiels, H. Duimel, P. Frederik, H. Veldman, J. H. J. Wokke, F. Spaans, A. Vincent, et al. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis Brain, October 1, 2005; 128(10): 2327 - 2337. [Abstract] [Full Text] [PDF]

				J S Muller, A Abicht, G Burke, J Cossins, P Richard, S K Baumeister, R Stucka, B Eymard, D Hantai, D Beeson, et al. The congenital myasthenic syndrome mutation RAPSN N88K derives from an ancient Indo-European founder J. Med. Genet., August 1, 2004; 41(8): e104 - e104. [Full Text] [PDF]

				R. Webster, M. Brydson, R. Croxen, J. Newsom-Davis, A. Vincent, and D. Beeson Mutation in the AChR ion channel gate underlies a fast channel congenital myasthenic syndrome Neurology, April 13, 2004; 62(7): 1090 - 1096. [Abstract] [Full Text] [PDF]

				D. P. Richman and M. A. Agius Treatment of autoimmune myasthenia gravis Neurology, December 23, 2003; 61(12): 1652 - 1661. [Abstract] [Full Text] [PDF]